Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: A sequential, randomized, double-blind clinical trial
References (38)
- et al.
Prevention of diabetic renal disease with special reference to microalbuminuria
Lancet
(1995) Lowering blood pressure for cardiovascular risk reduction
J Hypertens Suppl
(2005)- et al.
Hypertensiona treatable component of the cardiometabolic syndrome: Challenges for the primary care physician
J Clin Hypertens (Greenwich)
(2006) - et al.
Epidemiologic, physiologic, and clinical implications of hypertension and insulin resistance
Curr Opin Cardiol
(1993) Lipids and lipoproteins in patients with type 2 diabetes
Diabetes Care
(2004)- et al.
Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: Prospective data from the Bruneck study
Diabetes Care
(2003) - et al.
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
N Eng J Med
(2002) - et al.
Pathways from obesity to hypertension: From the perspective of a vicious triangle
Int J Obes Relat Metab Disord
(2002) - et al.
Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease
Rev Contemp Pharmacother
(1998) Screening for diabetes (Position Statement)
Diabetes Care
(2001)
1999 World Health OrganizationInternational Society of Hypertension Guidelines for the Management of Hypertension
J Hypertens
Vibratory perception in diabetics during arrested blood flow to the limb
Acta Med Scand
Nutrition recommendations and principles for people with diabetes mellitus (Position Statement)
Diabetes Care
A desktop guide to Type 2 diabetes mellitus
Diabet Med
Determination of total serum insulin (IRI) in insulin-treated diabetic patients
Diabetologia
The glycosylation of hemoglobin: Relevance to diabetes mellitus
Science
Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA II)
J Clin Chem Clin Biochem
Triglycerides: Determination after enzymatic hydrolysis
Cited by (18)
Innervation of the arterial wall and its modification in atherosclerosis
2015, Autonomic Neuroscience: Basic and ClinicalCitation Excerpt :In animal models, blockage of perivascular vasomotor nerves results in seriously impaired endothelial function (Burnstock, 1990). In hypertensive patients, treatment with monoxidine, an α2-adrenoreceptor agonist, has been shown to have beneficial effects on endothelial function (Topal et al., 2006; Derosa et al., 2007). Therefore, sympathetic nerves could influence endothelial function involved in the regulation of vascular tone.
An "I" on Cardiac Hypertrophic Remodelling: Imidazoline Receptors and Heart Disease
2012, Canadian Journal of CardiologyCitation Excerpt :In addition, moxonidine results in a clinically relevant reduction in blood pressure and muscle sympathetic nerve activity in patients with renal disease, in end-stage renal disease patients, and patients with resistant hypertension;34-36 and may be an “add-on” treatment in elderly patients whose hypertension is poorly controlled despite treatment with 2 or more antihypertensive agents.35 Moxonidine can be combined with peripheral vasodilators and thiazide diuretics,37 which otherwise may further stimulate SNS activity,38 as well as with angiotensin blockers.28,34 Furthermore, moxonidine potentiates the antidepressant effects of fluoxetine and paroxetine, at doses inefficient by themselves.39
Comparable renovascular protective effects of moxonidine and simvastatin in rats exposed to cigarette smoke
2010, Vascular PharmacologyCardiovascular Therapies and Associated Glucose Homeostasis. Implications Across the Dysglycemia Continuum
2009, Journal of the American College of CardiologyCitation Excerpt :The mechanism of this benefit is also unclear, but in vitro and animal studies suggest ranolazine may increase glucose-stimulated insulin secretion and this may be responsible for the improved glucose homeostasis observed (68). Moxonidine is a selective imidazole II-receptor agonist that lowers BP by a central mechanism but also has been shown to have dose-dependent metabolic effects including reduction in glucose, insulin, and glycated hemoglobin in those with diabetes and MetSyn (69,70). The prevalence of pre-diabetes and diabetes continues to increase, driven largely by obesity and physical inactivity.
Telmisartan and moksonidin’s opportunities in treatment of arterial hypertension
2020, Kardiologiya i Serdechno-Sosudistaya KhirurgiyaDevelopment of insulin resistance in Nischarin mutant female mice
2019, International Journal of Obesity